Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Is It Safe to Take 650 mg of Paracetamol on a Regular Basis?

Author(s): Sunil Kumar Kadiri, Deepika Uchil*, Dhani Movuram Guruprakash, Dhritija Sathavalli and Durgesh Singh

Volume 5, Issue 3, 2024

Published on: 28 November, 2023

Article ID: e281123223945 Pages: 9

DOI: 10.2174/0126667975267870231115052446

Price: $65

Abstract

The commonest medication to treat moderate to severe pain and fever in adults and children is paracetamol and it has been observed that there is a rapid increase in the intake of paracetamol- 650 since the COVID-19 pandemic and it is continuing till date. This analgesic and antipyretic medication showed an increase of 150% in its consumption during the pandemic, simultaneously escalating its self-medication. Concerns have been expressed about the indirect advertising of prescription medications, their illogical use, and improper self-medication, which has resulted in overdose and certain serious side effects. Chronic pain and pyrexia are the most common symptoms witnessed during the COVID-19 pandemic. The intake of paracetamol-650 has also been increased as a prophylactic measure due to the widespread fear generated during COVID-19. The usage of paracetamol has been shifted from 500 mg to 650 mg for mild and moderate pain and fever during and after the end of the pandemic. This raises concerns about the misuse of paracetamol-650mg which may cause damage to the liver, stomach, and kidney chronically. So, this review article aims to generate awareness among the public and physicians about the rationale of paracetamol as an analgesic and antipyretic.

Graphical Abstract

[1]
Eccles R. Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. J Clin Pharm Ther 2006; 31(4): 309-19.
[http://dx.doi.org/10.1111/j.1365-2710.2006.00754.x ] [PMID: 16882099]
[2]
Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. JAMA 1995; 273(12): 929-33.
[http://dx.doi.org/10.1001/jama.1995.03520360043037 ] [PMID: 7884951]
[3]
Ulukol B, Köksal Y, Cin S. Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections. Eur J Clin Pharmacol 1999; 55(9): 615-8.
[http://dx.doi.org/10.1007/s002280050681 ] [PMID: 10638387]
[4]
Miners JO, Penhall R, Robson RA, Birkett DJ. Comparison of paracetamol metabolism in young adult and elderly males. Eur J Clin Pharmacol 1988; 35(2): 157-60.
[http://dx.doi.org/10.1007/BF00609245 ] [PMID: 3191934]
[5]
Hudgings L, Kelsberg G, Safranek S, Neher JO. Clinical inquiries. Do antipyretics prolong febrile illness? J Fam Pract 2004; 53(1): 57-58, 61.
[PMID: 14709270]
[6]
Graham NMH, Burrell CJ, Douglas RM, Debelle P, Davies L. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990; 162(6): 1277-82.
[http://dx.doi.org/10.1093/infdis/162.6.1277 ] [PMID: 2172402]
[7]
Schachtel BP, Fillingim JM, Beiter DJ, Lane AC, Schwartz LA. Rating scales for analgesics in sore throat. Clin Pharmacol Ther 1984; 36(2): 151-6.
[http://dx.doi.org/10.1038/clpt.1984.154 ] [PMID: 6744773]
[8]
Schachtel BP, Fillingim JM, Lane AC, Thoden WR, Baybutt RI. Caffeine as an analgesic adjuvant. A double-blind study comparing aspirin with caffeine to aspirin and placebo in patients with sore throat. Arch Intern Med 1991; 151(4): 733-7.
[http://dx.doi.org/10.1001/archinte.1991.00400040081017 ] [PMID: 2012456]
[9]
Eccles R, Loose I, Jawad M, Nyman L. Effects of acetylsalicylic acid on sore throat pain and other pain symptoms associated with acute upper respiratory tract infection. Pain Med 2003; 4(2): 118-24.
[http://dx.doi.org/10.1046/j.1526-4637.2003.03019.x ] [PMID: 12873261]
[10]
Edwards JE, Oldman A, Smith L, et al. Single dose oral aspirin for acute pain. Cochrane Database Syst Rev 2000; (2): CD002067.
[PMID: 10796855]
[11]
Younkin SW, Betts RF, Roth FK, Douglas RG Jr. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother 1983; 23(4): 577-82.
[http://dx.doi.org/10.1128/AAC.23.4.577 ] [PMID: 6859836]
[12]
Milvio C. Treatment of influenza syndrome. A double-blind controlled trial of nimesulide v. aspirin. Clin Trials J 1985; 22(1): 111-7.
[13]
Bachert C, Chuchalin AG, Eisebitt R, Netayzhenko VZ, Voelker M. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study. Clin Ther 2005; 27(7): 993-1003.
[http://dx.doi.org/10.1016/j.clinthera.2005.06.002 ] [PMID: 16154478]
[14]
Colgan MT, Mintz AA. The comparative antipyretic effect of N-acetyl-p-aminophenol and acetylsalicylic acid. J Pediatr 1957; 50(5): 552-5.
[http://dx.doi.org/10.1016/S0022-3476(57)80219-4 ] [PMID: 13417020]
[15]
Yaffe SJ. Comparative efficacy of aspirin and acetaminophen in the reduction of fever in children. Arch Intern Med 1981; 141(3): 286-92.
[http://dx.doi.org/10.1001/archinte.1981.00340030018005 ] [PMID: 7008732]
[16]
Prescott LF. Paracetamol. Am J Ther 2000; 7(2): 143-8.
[http://dx.doi.org/10.1097/00045391-200007020-00011 ] [PMID: 11319582]
[17]
Melis R. Ibuprofen and/or acetaminophen: What price for “euthermia”? J Pediatr 1997; 131(2): 332.
[http://dx.doi.org/10.1016/S0022-3476(97)70179-3 ] [PMID: 9290629]
[18]
Cooper SA. Comparative analgesic efficacies of aspirin and acetaminophen. Arch Intern Med 1981; 141(3): 282-5.
[http://dx.doi.org/10.1001/archinte.1981.00340030014004 ] [PMID: 7008731]
[19]
Peters BH, Fraim CJ, Masel BE. Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. Am J Med 1983; 74(6): 36-42.
[http://dx.doi.org/10.1016/0002-9343(83)90526-0 ] [PMID: 6344625]
[20]
Clissold SP. Paracetamol and phenacetin. Drugs 1986; 32(S4): 46-59.
[http://dx.doi.org/10.2165/00003495-198600324-00005 ] [PMID: 3552585]
[21]
Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children’s pain or fever: A meta-analysis. Arch Pediatr Adolesc Med 2004; 158(6): 521-6.
[http://dx.doi.org/10.1001/archpedi.158.6.521 ] [PMID: 15184213]
[22]
Pandolfi S, Chirumbolo S, Ricevuti G, et al. Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal. Basic Clin Pharmacol Toxicol 2022; 130(2): 225-39.
[http://dx.doi.org/10.1111/bcpt.13690 ] [PMID: 34811895]
[23]
Romano S, Galante H, Figueira D, Mendes Z, Rodrigues AT. Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies. Res Social Adm Pharm 2021; 17(1): 1876-81.
[http://dx.doi.org/10.1016/j.sapharm.2020.05.024 ] [PMID: 32482587]
[24]
Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med 2020; 382(17): 1663-5.
[http://dx.doi.org/10.1056/NEJMc2005073 ] [PMID: 32187458]
[25]
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032 ] [PMID: 32109013]
[26]
Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild‐to‐moderate coronavirus disease 2019. J Intern Med 2020; 288(3): 335-44.
[http://dx.doi.org/10.1111/joim.13089 ] [PMID: 32352202]
[27]
Duong M, Gulmez SE, Salvo F, et al. Usage patterns of paracetamol in France. Br J Clin Pharmacol 2016; 82(2): 498-503.
[http://dx.doi.org/10.1111/bcp.12957 ] [PMID: 27059520]
[28]
Diener HC, Schneider R, Aicher B. Per-capita consumption of analgesics: A nine-country survey over 20 years. J Headache Pain 2008; 9(4): 225-31.
[http://dx.doi.org/10.1007/s10194-008-0046-6 ] [PMID: 18618072]
[29]
Shader RI. Acetaminophen (paracetamol), COVID-19, and misleading conclusions: A commentary. J Clin Psychopharmacol 2021; 41(2): 98-9.
[http://dx.doi.org/10.1097/JCP.0000000000001345 ] [PMID: 33443969]
[30]
Keaveney A, Peters E, Way B. Effects of acetaminophen on risk taking. Soc Cogn Affect Neurosci 2020; 15(7): 725-32.
[http://dx.doi.org/10.1093/scan/nsaa108 ] [PMID: 32888031]
[31]
Rodríguez-Morales AJ, Cardona-Ospina JA, Murillo-Muñoz MM. Gastroenterologists, hepatologists, COVID-19 and the use of acetaminophen. Clin Gastroenterol Hepatol 2020; 18(9): 2142-3.
[http://dx.doi.org/10.1016/j.cgh.2020.04.025 ] [PMID: 32387226]
[32]
Peluso L, Abella BS, Ferrer R, Kucher N, Sunde K, Taccone FS. Fever management in COVID-19 patients. Minerva Anestesiol 2021; 87(1): 1-3.
[http://dx.doi.org/10.23736/S0375-9393.20.15195-2 ] [PMID: 33231411]
[33]
Robertson JA, Sauer D, Gold JA, Nonas SA. The role of cyclooxygenase-2 in mechanical ventilation-induced lung injury. Am J Respir Cell Mol Biol 2012; 47(3): 387-94.
[http://dx.doi.org/10.1165/rcmb.2011-0005OC ] [PMID: 22556158]
[34]
Zand Irani A, Borchert G, Craven B, Gibbons H. Flucloxacillin and paracetamol induced pyroglutamic acidosis. BMJ Case Rep 2021; 14(1): e237536.
[http://dx.doi.org/10.1136/bcr-2020-237536 ] [PMID: 33419747]
[35]
Mendoza CD, Heard K, Dart RC. Coma, metabolic acidosis and normal liver function in a child with a large serum acetaminophen level. Ann Emerg Med 2006; 48(5): 637.
[http://dx.doi.org/10.1016/j.annemergmed.2006.06.045 ] [PMID: 17052573]
[36]
Steiner AA. Should we let fever run its course in the early stages of COVID-19? J R Soc Med 2020; 113(10): 407-9.
[http://dx.doi.org/10.1177/0141076820951544 ] [PMID: 32930066]
[37]
Hodgman MJ, Garrard AR. A review of acetaminophen poisoning. Crit Care Clin 2012; 28(4): 499-516.
[http://dx.doi.org/10.1016/j.ccc.2012.07.006 ] [PMID: 22998987]
[38]
Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020; 11: 585354.
[http://dx.doi.org/10.3389/fimmu.2020.585354 ] [PMID: 33163000]
[39]
Quaglietta L, Martinelli M, Staiano A. Serious infectious events and ibuprofen administration in pediatrics: A narrative review in the era of COVID-19 pandemic. Ital J Pediatr 2021; 47(1): 20.
[http://dx.doi.org/10.1186/s13052-021-00974-0 ] [PMID: 33514404]
[40]
Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; 9(7): 763-72.
[http://dx.doi.org/10.1016/S2213-2600(21)00160-0 ] [PMID: 33844996]
[41]
Wojcieszyńska D, Guzik H, Guzik U. Non-steroidal anti-inflammatory drugs in the era of the COVID-19 pandemic in the context of the human and the environment. Sci Total Environ 2022; 834: 155317.
[http://dx.doi.org/10.1016/j.scitotenv.2022.155317 ] [PMID: 35452725]
[42]
Ragni E, Mangiavini L, Viganò M, et al. Management of osteoarthritis during the COVID‐19 pandemic. Clin Pharmacol Ther 2020; 108(4): 719-29.
[http://dx.doi.org/10.1002/cpt.1910 ] [PMID: 32438454]
[43]
Simnani FZ, Singh D, Kaur R. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: A review. 3 Biotech 2022; 12(1): 15.
[44]
Pandolfi S, Valdenassi L, Bjørklund G, et al. COVID-19 medical and pharmacological management in the European countries compared to Italy: An overview. Int J Environ Res Public Health 2022; 19(7): 4262.
[http://dx.doi.org/10.3390/ijerph19074262 ] [PMID: 35409942]
[45]
Aouissi HA, Belhaouchet I. What about rheumatic diseases and COVID-19? New Microbes New Infect 2021; 41: 100846.
[http://dx.doi.org/10.1016/j.nmni.2021.100846 ] [PMID: 33614039]
[46]
De Sarro C, Papadopoli R, Morgante MC, Nobile CGA, De Sarro G, Pileggi C. Vaccinations status against vaccine-preventable diseases and willingness to be vaccinated in an italian sample of frail subjects. Vaccines 2022; 10(8): 1311.
[http://dx.doi.org/10.3390/vaccines10081311 ] [PMID: 36016199]
[47]
Iguacel I, Maldonado AL, Ruiz-Cabello AL, Casaus M, Moreno LA, Martínez-Jarreta B. Association between COVID-19 vaccine side effects and body mass index in Spain. Vaccines 2021; 9(11): 1321.
[http://dx.doi.org/10.3390/vaccines9111321 ] [PMID: 34835252]
[48]
Dimova S, Hoet PHM, Dinsdale D, Nemery B. Acetaminophen decreases intracellular glutathione levels and modulates cytokine production in human alveolar macrophages and type II pneumocytes in vitro. Int J Biochem Cell Biol 2005; 37(8): 1727-37.
[http://dx.doi.org/10.1016/j.biocel.2005.03.005 ] [PMID: 15878691]
[49]
Geddes L. The fever paradox. New Sci 2020; 246(3277): 39-41.
[http://dx.doi.org/10.1016/S0262-4079(20)30731-4 ] [PMID: 32372807]
[50]
Egeberg O. The effect of unspecific fever induction on the blood clotting system. Scand J Clin Lab Invest 1962; 14(5): 471-4.
[http://dx.doi.org/10.3109/00365516209051265]
[51]
Campbell RA, Boilard E, Rondina MT. Is there a role for the ACE2 receptor in SARS‐CoV‐2 interactions with platelets? J Thromb Haemost 2021; 19(1): 46-50.
[http://dx.doi.org/10.1111/jth.15156 ] [PMID: 33119197]
[52]
Shen S, Zhang J, Fang Y, et al. SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism. J Hematol Oncol 2021; 14(1): 72.
[http://dx.doi.org/10.1186/s13045-021-01082-6 ] [PMID: 33926500]
[53]
Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: A population-based cohort study. Chest 2011; 139(2): 289-95.
[http://dx.doi.org/10.1378/chest.10-0891 ] [PMID: 20688925]
[54]
Munsterhjelm E, Munsterhjelm NM, Niemi TT, Ylikorkala O, Neuvonen PJ, Rosenberg PH. Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers. Anesthesiology 2005; 103(4): 712-7.
[http://dx.doi.org/10.1097/00000542-200510000-00009 ] [PMID: 16192763]
[55]
Munsterhjelm E, Niemi TT, Ylikorkala O, Silvanto M, Rosenberg PH. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro. Acta Anaesthesiol Scand 2005; 49(6): 840-6. b
[http://dx.doi.org/10.1111/j.1399-6576.2005.00707.x] [PMID: 15954969]
[56]
Ghaffar UB, Tadvi NA. Paracetamol toxicity: A review. J Contemp Med Dent 2014; 2: 12-5.
[57]
Gunn VL, Taha SH, Liebelt EL, Serwint JR. Toxicity of over-the-counter cough and cold medications. Pediatrics 2001; 108(3): e52.
[http://dx.doi.org/10.1542/peds.108.3.e52 ] [PMID: 11533370]
[58]
Smith W, Leyva R, Kellstein D, Arthur E, Cruz-Rivera M. Efficacy of a fixed-dose combination of ibuprofen and acetaminophen compared with individual monocomponents in adult male subjects with endotoxin-induced fever: A randomized controlled trial. Clin Ther 2021; 43(7): 1213-27.
[http://dx.doi.org/10.1016/j.clinthera.2021.05.004 ] [PMID: 34304913]
[59]
Ooi EE, Dhar A, Petruschke R, Locht C, Buchy P, Low JG. Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. npj. Vaccines 2022; 7(1): 31.
[PMID: 36679876]
[60]
Warwick C. Paracetamol and fever management. J R Soc Promot Health 2008; 128(6): 320-3.
[http://dx.doi.org/10.1177/1466424008092794 ] [PMID: 19058473]
[61]
Kingsley Ogemdi I. A Review on the Properties and Uses of Paracetamol. Int J Pharm Chem 2019; 5(3): 31-5.
[http://dx.doi.org/10.11648/j.ijpc.20190503.12]
[62]
Sharma CV, Mehta V. Paracetamol: Mechanisms and updates. Contin Educ Anaesth Crit Care Pain 2014; 14(4): 153-8.
[http://dx.doi.org/10.1093/bjaceaccp/mkt049]
[63]
Manna S, Tripathy S, Dor VJ, Padhi BK. Paracetamol usages regulation: A need of the hour. Ann Med Surg 2022; 84(Dec): 104805.
[http://dx.doi.org/10.1016/j.amsu.2022.104805 ] [PMID: 36387958]
[64]
McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. Long‐term adverse effects of paracetamol – a review. Br J Clin Pharmacol 2018; 84(10): 2218-30.
[http://dx.doi.org/10.1111/bcp.13656 ] [PMID: 29863746]
[65]
Nilsen K, Staff AC, Krogsrud SK. Paracetamol use in pregnancy: Not as safe as we may think? Acta Obstet Gynecol Scand 2023; 102(6): 652-6.
[http://dx.doi.org/10.1111/aogs.14557 ] [PMID: 36941046]
[66]
Turtle EJ, Dear JW, Webb DJ. A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. Br J Clin Pharmacol 2013; 75(6): 1396-405.
[http://dx.doi.org/10.1111/bcp.12032 ] [PMID: 23145789]
[67]
Conaghan PG, Arden N, Avouac B, Migliore A, Rizzoli R. Safety of paracetamol in osteoarthritis: What does the literature say? Drugs Aging 2019; 36(S1): 7-14.
[http://dx.doi.org/10.1007/s40266-019-00658-9 ] [PMID: 31073920]
[68]
Offor SJ, Amadi CN, Chijioke-Nwauche I, Manautou JE, Orisakwe OE. Potential deleterious effects of paracetamol dose regime used in Nigeria versus that of the United States of America. Toxicol Rep 2022; 9: 1035-44.
[http://dx.doi.org/10.1016/j.toxrep.2022.04.025 ] [PMID: 36561959]
[69]
Ali I, Alharbi OML. COVID-19: Disease, management, treatment, and social impact. Sci Total Environ 2020; 728: 138861.
[http://dx.doi.org/10.1016/j.scitotenv.2020.138861 ] [PMID: 32344226]
[70]
Mattiuzzi C, Lippi G. How much has COVID-19 contributed to increase the worldwide consumption of paracetamol and ibuprofen? evidence from an infodemiological analysis. Hosp Pharm 2022.
[PMID: 36644739]
[71]
Saleh EA, Haddadin RN, Saleh B, Elayeh E. Changes in drug demand when a pandemic coincides with other outbreaks in a war zone country: A cross-sectional pilot study. J Pharm Policy Pract 2022; 15(1): 89.
[http://dx.doi.org/10.1186/s40545-022-00487-z ] [PMID: 36419090]
[72]
Przybyła GW, Szychowski KA, Gmiński J. Paracetamol – An old drug with new mechanisms of action. Clin Exp Pharmacol Physiol 2021; 48(1): 3-19.
[http://dx.doi.org/10.1111/1440-1681.13392 ] [PMID: 34545616]
[73]
Pandolfi S, Simonetti V, Ricevuti G, Chirumbolo S. Paracetamol in the home treatment of early COVID‐19 symptoms: A possible foe rather than a friend for elderly patients? J Med Virol 2021; 93(10): 5704-6.
[http://dx.doi.org/10.1002/jmv.27158 ] [PMID: 34170556]
[74]
Mostafa EMA, Tawfik AM, Abd-Elrahman KM. Egyptian perspectives on potential risk of paracetamol/acetaminophen-induced toxicities: Lessons learnt during COVID-19 pandemic. Toxicol Rep 2022; 9: 541-8.
[http://dx.doi.org/10.1016/j.toxrep.2022.03.035 ] [PMID: 35371923]
[75]
Mir SA, Shakeel D, Qadri ZL. Self-medication practices during COVID-19 pandemic: A cross-sectional survey. Asian J Pharm Clin Res 2021; 29(1): 80-2.
[76]
Patel PA, Zalavadia J, Prajapati A, et al. Self-medication among medical students during the COVID19 pandemic. Natl J Community Med 2023; 14(5): 335-9.
[http://dx.doi.org/10.55489/njcm.140520232855]
[77]
Ambali AP, Santhosh BT. The safety profile of COVID-19 Vaccination among 1373 elderly population. Medica 2022; 11(1): 7.
[78]
Roy SP, Kadiri SK, Karkar VV, Konijeti SR. Antiparkinsonian activity of Tabebuiaimpetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. Ann Pharm Fr 2022; 80(6): 853-63.
[79]
Damani A, Ghoshal A, Salins N, et al. Approaches and best practices for managing cancer pain within the constraints of the COVID-19 pandemic in India. Indian J Palliat Care 2020; 26(S1): S106-15.
[PMID: 33088099]
[80]
Jethi N, Banik S, Yadav P, Kaur S, Kaur K, Ratani KA. Post obturation analgesia in patients recently vaccinated against Covid-19, after Root canal treatment: a short observational study. Eur J Mol Clin Med 2022; 9(07)
[81]
Singh S, Kishore D, Singh RK. Potential for further mismanagement of fever during COVID-19 pandemic: Possible causes and impacts. Front Med 2022; 9: 751929.
[http://dx.doi.org/10.3389/fmed.2022.751929 ] [PMID: 35308547]
[82]
Panse S, Kanchi M, Chacko J. Intensive care unit setup for COVID-19. J Cardiac Crit Care TSS 2020; 4(01): 05-11.
[83]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191 ] [PMID: 32004427]
[84]
Priya S, Sindhushavishwanatha S, Kadiri SK, Mallik A. survey on prophylactic measures taken by the hyderabadi’s during the 2nd wave of COVID-19. Int J Health Sci 2022; 6(S2): 13824-40.
[http://dx.doi.org/10.53730/ijhs.v6nS2.8849]
[85]
Sevella P, Rallabhandi SSH, Jahagirdar V, et al. Acute mesenteric ischemia as an early complication of COVID-19. Cureus 2021; 13(9): e18082.
[http://dx.doi.org/10.7759/cureus.18082 ] [PMID: 34671542]
[86]
Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: An overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv 2020; 11(4): 245-68.
[http://dx.doi.org/10.4155/tde-2020-0035 ] [PMID: 32397911]
[87]
PATEL H, Makwana H, Shah K, Malhotra S. Transient liver enzyme derangement following Remdesivir use: A case series. J Pharmacovigil Drug Saf 2021; 2(3): 30-4.
[88]
Bianconi V, Violi F, Fallarino F, Pignatelli P, Sahebkar A, Pirro M. Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19? Drugs 2020; 80(14): 1383-96.
[http://dx.doi.org/10.1007/s40265-020-01365-1 ] [PMID: 32705604]
[89]
Vanden Eynde JJ. COVID-19: A brief overview of the discovery clinical trial. Pharmaceuticals 2020; 13(4): 65.
[http://dx.doi.org/10.3390/ph13040065 ] [PMID: 32290348]
[90]
Sestili P, Fimognari C. Paracetamol-induced glutathione consumption: is there a link with severe COVID-19 illness? Front Pharmacol 2020; 11: 579944.
[http://dx.doi.org/10.3389/fphar.2020.579944 ] [PMID: 33117175]
[91]
Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment? Br J Clin Pharmacol 2016; 81(2): 210-22.
[http://dx.doi.org/10.1111/bcp.12802 ] [PMID: 26460177]
[92]
Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity – where do we go from here? Expert Opin Drug Saf 2007; 6(4): 341-55.
[http://dx.doi.org/10.1517/14740338.6.4.341 ] [PMID: 17688378]
[93]
Mitchell RA, Rathi S, Dahiya M, Zhu J, Hussaini T, Yoshida EM. Public awareness of acetaminophen and risks of drug induced liver injury: Results of a large outpatient clinic survey. PLoS One 2020; 15(3): e0229070.
[http://dx.doi.org/10.1371/journal.pone.0229070 ] [PMID: 32130228]
[94]
Shek KLA, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. Pharmacotherapy 1999; 19(10): 1153-8.
[http://dx.doi.org/10.1592/phco.19.15.1153.30584 ] [PMID: 10512064]
[95]
Lee WM. Acetaminophen (APAP) hepatotoxicity—Isn’t it time for APAP to go away? J Hepatol 2017; 67(6): 1324-31.
[http://dx.doi.org/10.1016/j.jhep.2017.07.005 ] [PMID: 28734939]
[96]
Schweighardt AE, Juba KM. A systematic review of the evidence behind use of reduced doses of acetaminophen in chronic liver disease. J Pain Palliat Care Pharmacother 2018; 32(4): 226-39.
[http://dx.doi.org/10.1080/15360288.2019.1611692 ] [PMID: 31206302]
[97]
Penna A, Buchanan N. Paracetamol poisoning in children and hepatotoxicity. Br J Clin Pharmacol 1991; 32(2): 143-9.
[http://dx.doi.org/10.1111/j.1365-2125.1991.tb03873.x ] [PMID: 1931463]
[98]
Use antipyretics for at-home management of children with low-risk fever and distress. Drugs Ther Perspect 2014; 30(12): 422-5.
[http://dx.doi.org/10.1007/s40267-014-0166-9]
[99]
Khan UD. My journey through untested COVID-19. Anaesth Pain Intensive Care 2020; 24(2): 252.
[http://dx.doi.org/10.35975/apic.v24i2.1272]
[100]
Shah S. COVID-19 and paediatric dentistry-traversing the challenges. A narrative review. Ann Med Surg 2020; 58: 22-33.
[http://dx.doi.org/10.1016/j.amsu.2020.08.007 ] [PMID: 32864126]
[101]
Pountoukidou A, Potamiti-Komi M, Sarri V, et al. Management and prevention of COVID-19 in pregnancy and pandemic obstetric care: A review of current practices. Healthcare 2021; 9(4): 467.
[102]
Seirafianpour F, Sodagar S, Pour Mohammad A, et al. Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review. Dermatol Ther 2020; 33(6): e13986.
[http://dx.doi.org/10.1111/dth.13986 ] [PMID: 32639077]
[103]
Erku DA, Belachew SA, Abrha S, et al. When fear and misinformation go viral: Pharmacists’ role in deterring medication misinformation during the ‘infodemic’ surrounding COVID-19. Res Social Adm Pharm 2021; 17(1): 1954-63.
[http://dx.doi.org/10.1016/j.sapharm.2020.04.032 ] [PMID: 32387230]
[104]
Kabwe JC, Lubeya MK, Phiri CC, et al. Psychosocial issues and coping mechanisms of pregnant and postnatal women diagnosed with COVID-19: A qualitative study. Womens Health 2022; 18.
[http://dx.doi.org/10.1177/17455057221111326 ] [PMID: 35838184]
[105]
Bhamra SK, Parmar J, Heinrich M. Impact of the coronavirus pandemic (COVID-19) on the professional practice and personal well-being of community pharmacy teams in the UK. Int J Pharm Pract 2021; 29(6): 556-65.
[http://dx.doi.org/10.1093/ijpp/riab062 ] [PMID: 34605895]
[106]
Mansfield KE, Mathur R, Tazare J, et al. Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: A population-based study. Lancet Digit Health 2021; 3(4): e217-30.
[http://dx.doi.org/10.1016/S2589-7500(21)00017-0 ] [PMID: 33612430]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy